Ignite Creation Date:
2024-05-06 @ 12:17 PM
Last Modification Date:
2024-10-26 @ 12:57 PM
Study NCT ID:
NCT03725059
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-12-18
First Post:
2018-10-29
Brief Title:
Study of Pembrolizumab MK-3475 Versus Placebo in Combination With Neoadjuvant Chemotherapy Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative ERHER2- Breast Cancer MK-3475-756KEYNOTE-756
Sponsor:
Organization:
Merck Sharp Dohme LLC